2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

9:00AM-11:00AM: Abstract Number: 1302

Subcutaneous Tanezumab vs NSAID for the Treatment of Osteoarthritis: Efficacy and General Safety Results from a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 1308

Subject Enrichment Criteria for Phase 3 Studies of Lorecivivint (SM04690), a Potential Disease-Modifying Knee Osteoarthritis Drug: A Post Hoc Study on the Effects of Baseline Comorbid Pain and Joint Space Width on Patient-Reported Outcomes

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 1114

Survival and Cost of Biologic DMARDs in a Military Medical Center: A Quality Improvement Initiative

Health Services Research Poster II – ACR/ARP

9:00AM-11:00AM: Abstract Number: 1674

Survival in ANCA-Associated Vasculitis in a Latin-American Center: 28 Years of Experience

Vasculitis – ANCA-Associated Poster II

9:00AM-11:00AM: Abstract Number: 1115

Switching Patterns Among Patients with Chronic Inflammatory Diseases Switching to an Infliximab Biosimilar or Remaining on Originator Infliximab (REMICADE)

Health Services Research Poster II – ACR/ARP

9:00AM-11:00AM: Abstract Number: 1473

Syndecan-1 Is a Potential Biomarker for Salivary Glandular Function and Disease Activity in Patients with Sjögren’s Syndrome

Sjögrenʼs Syndrome – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 1259

Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO): A Case Series

Miscellaneous Rheumatic & Inflammatory Disease Poster II: Autoinflammation Related Diseases & Therapies

9:00AM-11:00AM: Abstract Number: 1336

Systematic Literature Review and Meta-Analysis of DAS28 Clinical Response Rates Among Advanced Therapies in Biologic-Naïve Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

9:00AM-11:00AM: Abstract Number: 1478

Systematic Literature Review and Network Meta-Analysis Comparing Incidence of Uveitis and IBD in Axial Spondyloarthritis Patients Treated with Anti-TNF versus Anti-IL17A in Placebo Controlled Randomized Trials

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1106

Systemic Lupus Erythematosus and Sjögren’s Syndrome in the Agricultural Health Study: Lower Risk Associated with Childhood Farm Residence and Raising Livestock

Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1611

Systemic Lupus Erythematosus Registries: Are the Measures Captured in the Real World Similar to Those in Clinical Trials?

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1459

Systemic Manifestations of Primary Sjögren Syndrome out of the ESSDAI Classification: Prevalence and Clinical Relevance in a Large International, Multi-ethnic Cohort of Patients

Sjögrenʼs Syndrome – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 1648

Systemic Sclerosis Auto-antibody Profiles Predict Interstitial Lung Disease Onset but Not Progression

Systemic Sclerosis & Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1737

Systemic Vascular Involvement in Kawasaki Disease: A Single Center Cohort

Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma

9:00AM-11:00AM: Abstract Number: 1620

T-cell Exhaustion in Prolonged Remission SLE Patients

SLE – Clinical Poster II: Comorbidities

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].